Active targeting to cancer involves exploiting specific interactions between receptors on the
surface of cancer cells and targeting moieties conjugated to the surface of vectors such that …

Targeted drug delivery is a tool to make treatment more specific, selective, and effective and
to prevent unwanted complications. Prostate specific membrane antigen (PSMA) is a useful …

Polymeric nanoparticles represent a form of targeted therapy due to their ability to passively
accumulate within the tumor interstitium via the enhanced permeability and retention (EPR) …

Prostate cancer (PC) is the second most commonly occurring cancer in men. Conventional
chemotherapy has wide variety of disadvantages such as high systemic toxicity and low …

To evaluate the chemotherapeutic efficacy of J591 fabricated poly (d, l)-lactic-co-glycolic
acid (PLGA) nanoparticles containing paclitaxel (Ab-PTX-NP) in vitro in PSMA (prostate …

Herein, we report the use of a theranostic nanocarrier (Folate-HBPE (CT20p)) to deliver a
therapeutic peptide to prostate cancer tumors that express PSMA (folate hydrolase 1). The …

Targeting therapy is a concept that has gained significant importance in recent years,
especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate …

Nanoparticles are designed to entrap drugs at a high concentration, escape clearance by
the immune system, be selectively taken up by cancer cells, and release bioactives in a rate …

Prostate specific membrane antigen (PSMA) is a marker for diagnosis and targeted delivery
of therapeutics to advanced/metastasized prostate cancer. We report a liposome-based …

Prostate cancer (PCa) is one of the most prevalent non‐drug delivery system cutaneous
malignancies. Undoubtedly, introducing novel treatment options to achieve higher …